We present evidence that ablation of Nrp1 in GAMs or focal treatment with EG00229, an inhibitor of Nrp1's b1 domain, modulates the way GAMs interact with glioma-derived tumor cells and tumor-cell generated cytokines, resulting in alterations in their polarization which correlate with slower disease progression. This evidence concerns the gene NRP1 and central nervous system cancer.